Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H2 2016, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS?CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Middle East Respiratory Syndrome (MERS) Overview 7
Therapeutics Development 8
Pipeline Products for Middle East Respiratory Syndrome (MERS) - Overview 8
Pipeline Products for Middle East Respiratory Syndrome (MERS) - Comparative Analysis 9
Middle East Respiratory Syndrome (MERS) - Therapeutics under Development by Companies 10
Middle East Respiratory Syndrome (MERS) - Therapeutics under Investigation by Universities/Institutes 11
Middle East Respiratory Syndrome (MERS) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Middle East Respiratory Syndrome (MERS) - Products under Development by Companies 14
Middle East Respiratory Syndrome (MERS) - Products under Investigation by Universities/Institutes 15
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development 16
Atriva Therapeutics GmbH 16
Autoimmune Technologies LLC 17
Humabs BioMed SA 18
Inovio Pharmaceuticals Inc 19
Nanotherapeutics Inc 20
Novavax Inc 21
Phelix Therapeutics LLC 22
Planet Biotechnology Inc 23
Regeneron Pharmaceuticals Inc 24
Romark Laboratories LC 25
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
3B-11 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ATR-006 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BNSP-333S1 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CSW-1 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
FBR-001 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
INO-4500 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
LCA-60 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Middle East respiratory syndrome vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Middle East respiratory syndrome vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
nitazoxanide - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
REGN-3048 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
REGN-3051 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
SAB-301 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Middle East Respiratory Syndrome (MERS) - Product Development Milestones 55
Featured News & Press Releases 55
Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute 55
Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment 55
Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Middle East Respiratory Syndrome (MERS), H2 2016 8
Number of Products under Development for Middle East Respiratory Syndrome (MERS) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H2 2016 16
Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H2 2016 17
Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H2 2016 18
Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 19
Middle East Respiratory Syndrome (MERS) - Pipeline by Nanotherapeutics Inc, H2 2016 20
Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H2 2016 21
Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H2 2016 22
Middle East Respiratory Syndrome (MERS) - Pipeline by Planet Biotechnology Inc, H2 2016 23
Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 24
Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Assessment by Combination Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35